Graviss Hospital (509546)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 7/9 indicates improving financial health and recent fundamental momentum.
• Latest quarter net profit of ₹3 Cr on sales of ₹19 Cr implies a healthy 15.8% net margin.
• Profit growth of 112.77% shows a sharp earnings rebound from a low base.
• P/B of 1.67 with book value of ₹31.90 provides some asset backing, though not cheap.
• Sales growth of 6.28% is positive, though modest.

Concerns

• ROE of 1.36% and ROCE of 1.18% reflect very poor return on capital.
• P/E of 0.00 indicates negligible trailing earnings; even annualising latest quarter profit gives a P/E above 30 at ₹375 Cr market cap.
• Dividend yield is 0.00%, offering no income support to shareholders.
• Promoter holding and debt/equity are not available, creating transparency concerns.
• Sales growth of only 6.28% means the high profit growth is likely a base effect, not durable compounding.

AI Analysis

At ₹53.17, Graviss Hospital carries a market cap of ₹375 Cr, or 1.67 times book value of ₹31.90. That may look reasonable at first, but Graham would demand earnings power behind the price. The reported P/E of 0.00 is a red flag: trailing earnings are negligible or not meaningful. The latest quarter shows ₹3 Cr net profit on ₹19 Cr sales, a healthy 15.8% margin, but annualising that gives roughly ₹12 Cr, implying a P/E above 30. The real business economics are far weaker. ROE is just 1.36% and ROCE 1.18%, meaning every ₹100 of capital generates only about a rupee of profit. That is poor capital efficiency, and it suggests no durable moat or pricing power. Sales growth is only 6.28%, so the 112.77% profit growth is largely a low-base recovery, not a sign of compounding quality. There is no dividend, so shareholders get no income support while waiting for a turnaround. The Piotroski F-Score of 7/9 is the only encouraging signal, pointing to improving financial health and operating momentum. But a high F-score on a mediocre business is not enough. I would need years of consistent returns on capital, clear promoter and debt data, and proof that earnings can stay above a level that justifies this price. At the top of its 52-week range, I find no margin of safety. This is a possible turnaround, not a compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer